DCE-MRI Study Abstract Selected by ASCO
ACR Image Metrix
™ is pleased to announce that the DCE-MRI study, as commissioned by
Bionomics Ltd.
, was submitted as an abstract by Bionomics to the American Society of Clinical Oncology (ASCO) and has been accepted to be presented as a part of the scientific program during the general poster session at the
ASCO Annual Meeting
, which will take place June 4-8, 2010, in Chicago, Illinois, at McCormick Place.
As a drug discovery and development organization focusing on new treatments for cancer and serious disorders of the central nervous system, Bionomics selected ACR Image Metrix to perform the imaging components of this study.
“Their extensive experience in the utilization of novel imaging techniques to serve as biomarkers and history of partnering with regulatory agencies to develop standards for imaging acquisition, data normalization, data extraction and the assessment of variability made the selection of ACR Image Metrix as our imaging CRO appropriate for this project,” stated Bionomics Vice President of Discovery Research, Gabriel Kremmidiotis, Ph.D.
The completion of this Phase I clinical trial, which involved
MRI (DCE-MRI)
quantitative analysis, was a two-stage dose escalation design involving Bionomics’ BNC 105P-001, a novel vascular disrupting agent staged in patients with advanced solid tumors.
“Teaming up with Bionomics to complete this study turned out to be a success and we are pleased with the results. This is a major milestone for ACR Image Metrix in our ability to conduct novel imaging for both pharmaceutical and biotech companies,” stated General Manager of ACR Image Metrix, Michael J. Morales.
ACR Image Metrix will also be exhibiting at the ASCO Annual Meeting, Booth 19097.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
